📍 WASHINGTON D.C., USA
01.11.2026
FDA Moves to Rescind Approval for Tavneos Amid Critical Clinical Data Irregularities
The United States Food and Drug Administration has initiated formal regulatory procedures to revoke its commercial approval of Tavneos, an autoimmune drug utilized to treat severe vasculitis, citing manipulated clinical ...